Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C21H25N5O8S2 |
Molecular Weight | 539.582 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](NC(=O)N3CCN(C3=O)S(C)(=O)=O)C4=CC=CC=C4)C(O)=O
InChI
InChIKey=YPBATNHYBCGSSN-VWPFQQQWSA-N
InChI=1S/C21H25N5O8S2/c1-21(2)14(18(29)30)26-16(28)13(17(26)35-21)22-15(27)12(11-7-5-4-6-8-11)23-19(31)24-9-10-25(20(24)32)36(3,33)34/h4-8,12-14,17H,9-10H2,1-3H3,(H,22,27)(H,23,31)(H,29,30)/t12-,13-,14+,17-/m1/s1
Molecular Formula | C21H25N5O8S2 |
Molecular Weight | 539.582 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:25:47 UTC 2023
by
admin
on
Fri Dec 15 16:25:47 UTC 2023
|
Record UNII |
OH2O403D1G
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QJ01CA10
Created by
admin on Fri Dec 15 16:25:47 UTC 2023 , Edited by admin on Fri Dec 15 16:25:47 UTC 2023
|
||
|
NCI_THESAURUS |
C1558
Created by
admin on Fri Dec 15 16:25:47 UTC 2023 , Edited by admin on Fri Dec 15 16:25:47 UTC 2023
|
||
|
WHO-ATC |
J01CA10
Created by
admin on Fri Dec 15 16:25:47 UTC 2023 , Edited by admin on Fri Dec 15 16:25:47 UTC 2023
|
||
|
LIVERTOX |
633
Created by
admin on Fri Dec 15 16:25:47 UTC 2023 , Edited by admin on Fri Dec 15 16:25:47 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID1023316
Created by
admin on Fri Dec 15 16:25:47 UTC 2023 , Edited by admin on Fri Dec 15 16:25:47 UTC 2023
|
PRIMARY | |||
|
1795
Created by
admin on Fri Dec 15 16:25:47 UTC 2023 , Edited by admin on Fri Dec 15 16:25:47 UTC 2023
|
PRIMARY | |||
|
656511
Created by
admin on Fri Dec 15 16:25:47 UTC 2023 , Edited by admin on Fri Dec 15 16:25:47 UTC 2023
|
PRIMARY | |||
|
D008802
Created by
admin on Fri Dec 15 16:25:47 UTC 2023 , Edited by admin on Fri Dec 15 16:25:47 UTC 2023
|
PRIMARY | |||
|
3898
Created by
admin on Fri Dec 15 16:25:47 UTC 2023 , Edited by admin on Fri Dec 15 16:25:47 UTC 2023
|
PRIMARY | |||
|
51481-65-3
Created by
admin on Fri Dec 15 16:25:47 UTC 2023 , Edited by admin on Fri Dec 15 16:25:47 UTC 2023
|
PRIMARY | |||
|
6927
Created by
admin on Fri Dec 15 16:25:47 UTC 2023 , Edited by admin on Fri Dec 15 16:25:47 UTC 2023
|
PRIMARY | RxNorm | ||
|
C653
Created by
admin on Fri Dec 15 16:25:47 UTC 2023 , Edited by admin on Fri Dec 15 16:25:47 UTC 2023
|
PRIMARY | |||
|
m7520
Created by
admin on Fri Dec 15 16:25:47 UTC 2023 , Edited by admin on Fri Dec 15 16:25:47 UTC 2023
|
PRIMARY | Merck Index | ||
|
Mezlocillin
Created by
admin on Fri Dec 15 16:25:47 UTC 2023 , Edited by admin on Fri Dec 15 16:25:47 UTC 2023
|
PRIMARY | |||
|
6919
Created by
admin on Fri Dec 15 16:25:47 UTC 2023 , Edited by admin on Fri Dec 15 16:25:47 UTC 2023
|
PRIMARY | |||
|
100000081163
Created by
admin on Fri Dec 15 16:25:47 UTC 2023 , Edited by admin on Fri Dec 15 16:25:47 UTC 2023
|
PRIMARY | |||
|
257-233-8
Created by
admin on Fri Dec 15 16:25:47 UTC 2023 , Edited by admin on Fri Dec 15 16:25:47 UTC 2023
|
PRIMARY | |||
|
CHEMBL1731
Created by
admin on Fri Dec 15 16:25:47 UTC 2023 , Edited by admin on Fri Dec 15 16:25:47 UTC 2023
|
PRIMARY | |||
|
OH2O403D1G
Created by
admin on Fri Dec 15 16:25:47 UTC 2023 , Edited by admin on Fri Dec 15 16:25:47 UTC 2023
|
PRIMARY | |||
|
DB00948
Created by
admin on Fri Dec 15 16:25:47 UTC 2023 , Edited by admin on Fri Dec 15 16:25:47 UTC 2023
|
PRIMARY | |||
|
SUB08938MIG
Created by
admin on Fri Dec 15 16:25:47 UTC 2023 , Edited by admin on Fri Dec 15 16:25:47 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
||
|
TRANSPORTER -> INHIBITOR |
Showed high in vivo inhibition potential due to the high unbound plasma concentrations attained at clinically relevant doses.
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |